Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Dyadic International Inc. (DYAI:NASDAQ), powered by AI.
Dyadic International Inc. is currently trading at $1.06. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Dyadic International Inc. on Alpha Lenz.
Dyadic International Inc.'s P/E ratio is -4.7.
“Dyadic International Inc. trades at a P/E of -4.7 (undervalued) with modest ROE of -397.8%.”
Ask for details →Dyadic International Inc. is a biotechnology company renowned for its work in enzyme technology and biopharmaceuticals. The primary function of Dyadic is to harness its proprietary C1 cell line, a robust fungal expression system, for commercializing biopharmaceuticals such as vaccines, enzymes, and therapeutic proteins. This technology aims to produce proteins more efficiently and cost-effectively than traditional methods, presenting significant opportunities across various industries. Dyadic holds a strong foothold in sectors like pharmaceuticals, agriculture, and industrial biotechnology, impacting how biologics are produced and processed. Strategically headquartered in Jupiter, Florida, the company collaborates extensively with global partners to advance research and development initiatives. With its focus on innovation and scalability, Dyadic International plays a pivotal role in the biotechnological landscape, driving advancements in the synthesis and production of critical biochemical compounds.
“Dyadic International Inc. trades at a P/E of -4.7 (undervalued) with modest ROE of -397.8%.”
Ask for details →Dyadic International Inc. (ticker: DYAI) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 6 employees. Market cap is $35M.
The current price is $1.06 with a P/E ratio of -4.7x and P/B of 28.06x.
ROE is -397.80% and operating margin is -579.88%. Annual revenue is $1M.